Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Part of paid clinical trials in New York, New York.
- Sponsor
- The New York Eye Cancer Center
- Study ID
- NCT00456495
- Phase
- PHASE1
- Status
- Completed
Conditions
- Conjunctival Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ranibizumab — DRUGSubconjunctival injection of drug every 2 to 4 weeks
Study Details
The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant conjunctival neoplasia by evaluating tumor destruction or reduction as documented by slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.
Key Dates
- First listed
- Apr 5, 2007
- Start date
- Mar 31, 2007
- Status verified
- Jun 2017
- Primary completion
- Sep 30, 2010
- Completion
- Sep 30, 2010
Study Design
- Enrollment
- 5 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Subconjunctival ranibizumabPatients will receive subconjunctival ranibizumab every 2-4 weeks.
Primary Outcome Measure
Number of Patients Assessed for Safety and Tolerability [ Time Frame: 2 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The New York Eye Cancer Center | New York | New York | 10021 | - |
Find similar trials in New York, NY
By research site